Zofran

ApprovedSmall molecule

PPar Pharmaceutical, Inc.

Zofran is one of 62 small molecule programs targeting Nausea and vomiting. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nausea and VomitingActive, not recruiting

Opioid Use DisorderActive, not recruiting

Nausea and VomitingPreclinical

Active, not recruiting

Opioid Use DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Nausea and Vomiting

#DrugCompanyPhaseTrials

Zofran

PPar Pharmaceutical, Inc.

Approved

1 2

Aloxi

AAvyxa

Preclinical

27 3

Ramosetron

Astellas

Preclinical

15 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

7 5

Phenergan

BBassett Healthcare

Preclinical

5 6

Haldol

DDePuy Orthopaedics

Preclinical

3 7

Oxycontin

PProtega

Preclinical

2 8

Anerem

AAcacia Pharma Ltd

Preclinical

2 9

Adriamycin

GGynecologic Oncology Group

Preclinical

2 10

Cytoxan

BBaxter Healthcare Corporation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Fasting Conditions6 trials

Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions

Completed·PPar Pharmaceutical, Inc.·Phase 1·NCT00659074·24 enrolled

Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00934921·24 enrolled

To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions

Completed· Novartis logo

Novartis·Phase 1·NCT00946387·26 enrolled

Show 3 more trials

To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions

Completed· Novartis logo

Novartis·Phase 1·NCT00947128·26 enrolled

Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions

Completed·PPar Pharmaceutical, Inc.·Phase 1·NCT00654277·32 enrolled

Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00934180·24 enrolled

Ondansetron3 trials

Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00649532·28 enrolled

Food Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00648583·28 enrolled

Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions

Completed·PPar Pharmaceutical, Inc.·Phase 1·NCT00653458·18 enrolled

Post Operative Pain2 trials

The Effect of Dexamethasone in Combination With Paracetamol and Ibuprofen on Postoperative Pain After Spine Surgery

Completed·RRigshospitalet, Denmark·Phase 4·NCT01953978·160 enrolled

Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain

Completed·IINSYS Therapeutics Inc·Phase 2·NCT03254459·100 enrolled

Cardiac Repolarization1 trial

Droperidol and Cardiac Repolarization

Completed·MMedical University of Gdansk·Phase 4·NCT01819857·75 enrolled

Multimodal Analgesia1 trial

Multimodal Analgesia Effect on Post Surgical Patient

Active, not recruiting·UUniversity of California, Davis·Phase 4·NCT04240626·60 enrolled

7 more indications

Infections1 trial

Improving Tolerance of Treatment of Pulmonary MAC Infections

Withdrawn·UUniversity of Florida·Phase 2·NCT01719042

Shoulder Arthroplasty1 trial

Pain Management After Shoulder Arthroplasty

Unknown status·RRothman Institute Orthopaedics·Phase 3·NCT04872270·160 enrolled

Nausea1 trial

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

Completed·AAMAG Pharmaceuticals, Inc.·Phase 1·NCT03973047·228 enrolled

Moderate to Severe Postoperative Pain1 trial

The Effect of Chlorzoxazone on Moderate to Severe Postoperative Pain After Spine Surgery

Completed·RRigshospitalet, Denmark·Phase 4·NCT01933542·110 enrolled

Nausea and vomiting1 trial

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

Completed·MM.D. Anderson Cancer Center·N/A·NCT02473042·188 enrolled

Opioid Use Disorder1 trial

PROUD Study - Preventing Opioid Use Disorders

Terminated·EEmory University·Phase 4·NCT04766996·57 enrolled

Advanced1 trial

Decreasing Narcotics in Advanced Pelvic Surgery

Completed·HHartford Hospital·Phase 4·NCT02110719·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for Zofran. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zofran compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zofran. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Par Pharmaceutical, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPar Pharmaceutical, Inc.

Zofran

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Fasting Conditions6 trials

Ondansetron3 trials

Post Operative Pain2 trials

Cardiac Repolarization1 trial

Multimodal Analgesia1 trial

Infections1 trial

Shoulder Arthroplasty1 trial

Nausea1 trial

Moderate to Severe Postoperative Pain1 trial

Nausea and vomiting1 trial

Opioid Use Disorder1 trial

Advanced1 trial

References

Drug Info

Quick Facts

Related News